CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Zidovudine

齐多夫定 杂质对照品Zidovudine Impurities

EP15 个杂质条目15 impurity entries

本页汇总 齐多夫定 的 15 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 15 impurity reference standards of Zidovudine with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 齐多夫定(Zidovudine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDevelopment and validation of a RP-HPLC method for the determination of zidovudine and its related substances in sustained-release tablets
    Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2011 · dos Santos JV et al.  ·  PMID 21415511  ·  DOI
  2. 杂质研究Impurity studiesA stability-indicating LC-MS/MS method for zidovudine: Identification, characterization and toxicity prediction of two major acid degradation products
    Journal of pharmaceutical analysis · 2017 · Devrukhakar PS et al.  ·  PMID 29404043  ·  DOI
  3. 杂质研究Impurity studiesIdentification, isolation, and characterization of potential degradation products in a triple combination lamivudine, zidovudine, and nevirapine tablet for oral suspension
    Die Pharmazie · 2010 · Aparna P et al.  ·  PMID 20503923
  4. 分析方法Analytical MethodsRapid quantitative determination of zidovudine, lamivudine and nevirapine drugs in pharmaceutical tablets by stability-indicating monolithic liquid chromatography: validation, greenness, blueness and whiteness studies
    Journal of chromatographic science · 2026 · Faria JC et al.  ·  PMID 42770255  ·  DOI
  5. 分析方法Analytical MethodsDevelopment and validation of an HPLC-UV method for simultaneous determination of zidovudine, lamivudine, and nevirapine in human plasma and its application to pharmacokinetic study in human volunteers
    Drug testing and analysis · 2013 · Nandi U et al.  ·  PMID 22374835  ·  DOI

齐多夫定 —— 原料药与杂质对照品Zidovudine — drug substance & impurities

共 16 个条目(含原料药本体)16 items incl. the drug substance
Zidovudine structure
EP原料药 APIAPI
齐多夫定Zidovudine
Zidovudine
CAS No.30516-87-1
Chemical FormulaC10H13N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 2 (Zidovudine EP Impurity B) structure
EPB
齐多夫定杂质2 (齐多夫定EP杂质B)Zidovudine Impurity 2 (Zidovudine EP Impurity B)
Zidovudine Impurity 2 (Zidovudine EP Impurity B)
CAS No.25526-94-7
Chemical FormulaC10H13ClN2O4
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 4(Zidovudine EP Impurity D) structure
EPD
齐多夫定杂质4(齐多夫定EP杂质D)Zidovudine Impurity 4(Zidovudine EP Impurity D)
Zidovudine Impurity 4(Zidovudine EP Impurity D)
CAS No.76-84-6
Chemical FormulaC19H16O
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 7(Zidovudine EP Impurity G) structure
EPG
齐多夫定杂质7(齐多夫定EP杂质G)Zidovudine Impurity 7(Zidovudine EP Impurity G)
Zidovudine Impurity 7(Zidovudine EP Impurity G)
CAS No.148665-49-0
Chemical FormulaC20H25N7O8
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 10(Zidovudine EP Impurity J) structure
EPJ
齐多夫定杂质10(齐多夫定EP杂质J)Zidovudine Impurity 10(Zidovudine EP Impurity J)
Zidovudine Impurity 10(Zidovudine EP Impurity J)
CAS No.29706-84-1
Chemical FormulaC29H27N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 11(Zidovudine EP Impurity K) structure
EPK
齐多夫定杂质11(齐多夫定EP杂质K)Zidovudine Impurity 11(Zidovudine EP Impurity K)
Zidovudine Impurity 11(Zidovudine EP Impurity K)
CAS No.596-31-6
Chemical FormulaC20H18O
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 12(Zidovudine Monophosphate) structure
12
齐多夫定杂质12(齐多夫定单磷酸盐)Zidovudine Impurity 12(Zidovudine Monophosphate)
Zidovudine Impurity 12(Zidovudine Monophosphate)
CAS No.29706-85-2
Chemical FormulaC10H14N5O7P
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 13(Zidovudine Glucuronide Sodium Salt) structure
13
齐多夫定杂质13(齐多夫定葡糖苷酸钠盐)Zidovudine Impurity 13(Zidovudine Glucuronide Sodium Salt)
Zidovudine Impurity 13(Zidovudine Glucuronide Sodium Salt)
CAS No.133525-01-6
Chemical FormulaC16H20N5NaO10
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 14 structure
14
齐多夫定杂质14Zidovudine Impurity 14
Zidovudine Impurity 14
CAS No.73971-82-1
Chemical FormulaC10H13N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 15 structure
15
齐多夫定杂质15Zidovudine Impurity 15
Zidovudine Impurity 15
CAS No.215176-58-2
Chemical FormulaC10H13N5O5
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 18 structure
18
齐多夫定杂质18Zidovudine Impurity 18
Zidovudine Impurity 18
CAS No.365-07-1
Chemical FormulaC10H15N2O8P
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 19 structure
19
齐多夫定杂质19Zidovudine Impurity 19
Zidovudine Impurity 19
CAS No.491-97-4
Chemical FormulaC10H16N2O11P2
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 20 structure
20
齐多夫定杂质20Zidovudine Impurity 20
Zidovudine Impurity 20
CAS No.244226-72-0
Chemical FormulaC16H27N3O14P2
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 22 structure
22
齐多夫定杂质22Zidovudine Impurity 22
Zidovudine Impurity 22
CAS No.1235890-74-0
Chemical FormulaC10H13N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 23 structure
23
齐多夫定杂质23Zidovudine Impurity 23
Zidovudine Impurity 23
CAS No.52417-07-9
Chemical FormulaC48H42N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Zidovudine Impurity 24 structure
24
齐多夫定杂质24Zidovudine Impurity 24
Zidovudine Impurity 24
CAS No.132979-39-6
Chemical FormulaC10H13N5O4
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

齐多夫定 —— 研究文献与合成路线Zidovudine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 齐多夫定 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Zidovudine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A stability-indicating LC-MS/MS method for zidovudine: Identification, characterization and toxicity prediction of two major acid degradation products
    Devrukhakar PS, Shiva Shankar M, Shankar G, et al. · Journal of pharmaceutical analysis · 2017 · 被引 9cited 9
  2. Mechanistic explanation to the variable degradation behaviour of stavudine and zidovudine under hydrolytic, oxidative and photolytic conditions
    Dunge A, Chakraborti AK, Singh S · Journal of pharmaceutical and biomedical analysis · 2004 · 被引 16cited 16
  3. Identification, isolation, and characterization of potential degradation products in a triple combination lamivudine, zidovudine, and nevirapine tablet for oral suspension
    Aparna P, Rao SV, Thomas KM, et al. · Die Pharmazie · 2010 · 被引 2cited 2
  4. Rapid quantitative determination of zidovudine, lamivudine and nevirapine drugs in pharmaceutical tablets by stability-indicating monolithic liquid chromatography: validation, greenness, blueness and whiteness studies
    Faria JC, Todeschini V, da Silva Sangoi M · Journal of chromatographic science · 2026
  5. Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance
    Eastman PS, Boyer E, Mole L, et al. · Journal of clinical microbiology · 1995 · 被引 15cited 15
  6. Spectra resolution for simultaneous spectrophotometric determination of lamivudine and zidovudine components in pharmaceutical formulation of human immunodeficiency virus drug based on using continuous wavelet transform and derivative transform techniques
    Sohrabi MR, Tayefeh Zarkesh M · Talanta · 2014 · 被引 6cited 6

合成与制备工艺专利Synthesis & process patents

  1. Process for purifying zidovudine palmitate raw materials and preparations thereof
    DENG YIHUI CHEN · 公开号 CN1827632CN1827632 · 2006
  2. Method for synthesizing higher fatty acid zidovudine ester
    XIAO ZHENG, XIUMIN WANG, WENFANG ZHU, LIJUAN WANG · 公开号 CN101260135CN101260135 · 2008
  3. Method for preparing Zidovudine azide intermediate by phase transition method
    JINLIANG LI, XIAJUN ZHOU · 公开号 CN101190934CN101190934 · 2008
  4. Polyesthylene glycol modified zidovudine conjugate and its prepn process and application
    LIU XINYONG CHANG · 公开号 CN101066459CN101066459 · 2007

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

齐多夫定 杂质谱研究要点Zidovudine — impurity profiling notes

下面这些是拿到 齐多夫定 的 16 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 16 impurity entries for Zidovudine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances